27.8 C
Vientiane
Saturday, July 5, 2025
spot_img
Home Blog Page 184

Kailo Medical Acquires REI AI to Transform the Future of Radiology Reporting

Strategic acquisition brings generative AI into structured workflows, reinforcing Kailo’s mission to deliver long-term impact through trusted, collaborative innovation.

MELBOURNE, May 21, 2025 /PRNewswire/ — Kailo Medical, a global leader in structured reporting for medical imaging, today announced its acquisition of REI AI, a pioneering generative AI company founded by Australian Radiology Registrar, Dr. Reuben Schmidt. The acquisition marks a significant milestone in Kailo’s ongoing commitment to transforming diagnostic reporting with tools that elevate both precision and clinical efficiency.

At the heart of this acquisition lies a shared philosophy: that meaningful technology begins with deep understanding. Both companies are rooted in clinical insight and built with a clear focus on supporting radiologists. With REI AI, Kailo expands its capabilities to include generative reporting technology that will seamlessly integrate into clinical workflows, unlocking new levels of speed, clarity, and consistency.

“This acquisition reflects our belief that the future of radiology should be shaped by those who live it every day.” said Bernard Duscher, Co-founder at Kailo Medical. “It empowers Radiologists to concentrate on the clinical question at hand, freeing them from the burden of transcription and allowing them to fully leverage their expertise.”

Dr. Reuben Schmidt joins Kailo as Director of Clinical AI, bringing invaluable real-world expertise in the use of large language models in the clinical workflow. His hands-on experience in radiology, combined with a pragmatic approach to AI, ensures that the resulting solutions will enhance rather than disrupt.

“REI AI was built by a radiologist, for radiologists,” said Schmidt. “Each feature is designed to remove friction, reduce errors, and help us focus on what really matters – providing high quality patient care.”

REI AI was created in response to rising imaging volumes, outdated reporting systems, and the growing need for smarter, more responsive tools. REI’s technology offers:

  • Natural dictation, elevated: Converts traditional voice dictation into structured, high-quality reports, preserving clinician workflow while improving speed and accuracy.
  • Real-time error detection: Uses LLMs to identify potential issues within reports before finalization, reducing rework and risk.
  • Clinician-led design: Built by a practicing radiologist with firsthand insight into workflow frustrations and opportunities for improvement.
  • Unified experience: A streamlined reporting environment that blends structure, flexibility, and clinical intent.
  • Clinically aligned impressions, personalized: Automatically generates impressions in the radiologist’s own language, drawing from prior reports, clinical context, available data systems, and preferred templates to ensure consistency, clarity and clinical excellence.

“This is next generation reporting far beyond the digital dictation and voice recognition of yesteryear” said Robert Newman, Co-founder at Kailo Medical. “REI’s technology expands Kailo’s product lineup while enhancing our existing solutions with new capabilities.”

Kailo Medical’s acquisition of REI AI reinforces its global strategy, deepening its impact across Australia, New Zealand, Canada, the United States, and South Africa, while positioning the company for growth in new international markets.

About Kailo Medical: Kailo Medical is a trusted provider of healthcare interoperability and structured reporting solutions for medical imaging. Headquartered in Melbourne, Kailo supports radiology teams across Australia, Canada, the United States, New Zealand, and South Africa. Kailo’s platform empowers medical imaging organizations to deliver high-quality diagnostic communication that powers progress and builds lasting trust.

About REI AI: REI AI is a clinician-founded generative AI company focused on radiology reporting. Built with a strong emphasis on clinical utility, usability, and ethical AI deployment, REI enables radiologists to work faster and smarter – without compromising quality.

Media Contact: Lauren Therriault, Vice President of Strategic Growth at Kailo Medical, sales@kailomedical.com

Logo – https://laotiantimes.com/wp-content/uploads/2025/05/kailo_medical_pty_ltd__kailo_medical_acquires_rei_ai_to_transfor.jpg 

UY Scuti Acquisition Corp. Announces the Separate Trading of its Ordinary Shares and Rights

NEW YORK, May 21, 2025 /PRNewswire/ — UY Scuti Acquisition Corp. (Nasdaq: UYSCU) (the “Company”) announced today that, commencing Tuesday, May 27, 2025, holders of the units sold in the Company’s initial public offering of 5,750,000 units (“Units”) may commence separate trading of the underlying component securities. Each Unit consists of one ordinary share, par value $0.0001 per ordinary share (“Share”), and one right to receive one-fifth (1/5th) of one Share upon the consummation of the Company’s initial business combination (“Right”). Those units not separated will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “UYSCU.”

The Shares and the Rights that are separated will trade on Nasdaq under the symbols “UYSC” and “UYSCR” respectively. Holders of units will need to have their securities brokers contact Continental Stock Transfer & Trust Company at 1 State Street, 30th Floor, New York, New York 10004, the Company’s transfer agent, in order to separate the Units into Shares and Rights.

The Units were initially offered by the Company in an underwritten offering through Maxim Group LLC, which acted as the sole book runner for the offering and as the representative of the underwriters in the offering. A registration statement on form S-1 relating to these securities (Sec File Number 333-284815) was declared effective by the Securities and Exchange Commission on March 31, 2025. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov.

UY Scuti Acquisition Corp.

UY Scuti Acquisition Corp. is a blank check company formed under the laws of the Cayman Islands for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, including those with respect to the Company’s search for an initial business combination, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements, including those set forth in the Risk Factors section of the Company’s registration statement and final prospectus for the Company’s initial public offering filed with the SEC. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.

AutoFull Teams Up with NiKo to Elevate Esports Seating Standards

NEW YORK, May 21, 2025 /PRNewswire/ — AutoFull announces its partnership with Nikola “NiKo” Kovač, one of the world’s most celebrated CS2 professionals. As AutoFull Global Product Ambassador, NiKo brings over a decade of elite competitive experience to help shape the future of ergonomic gaming chairs.


NiKo’s Choice: AutoFull M6 and G7

With more than 30,000 hours of in-game time, NiKo knows the toll of professional gaming. To stay at his best, he trusts the AutoFull M6 and G7—chairs built to support posture, reduce fatigue, and enhance focus during long sessions.

“In the past, I sat in chairs that couldn’t support my posture. Back pain became my unwanted teammate. Now? The game has changed,” says NiKo.

 “The AutoFull M6 and AutoFull G7 are designed to relieve pressure and help me stay locked in.”

AutoFull M6: Engineered for Elite Performance

Crafted for professional players and serious gamers, the AutoFull M6 blends premium ergonomics with innovative features:

  • Lumbar Massage System: World-first tech offering deep-tissue massage with three intensity levels. The support adjusts automatically to your posture, even while leaning forward.
  • 3D ErgoCloud Neck Pillow: Provides targeted neck support to reduce spinal pressure and shoulder fatigue.
  • World’s First Ventilated & Heated Esports Throne: Integrated cooling and heating system keeps your body at the right temperature, no matter the season.
  • 360° Adjustable Armrests: Adapted to any gaming posture with swivel, tilt, slide, and dual-angle rotation — for perfect support in FPS, MOBA, and more.

AutoFull G7: Built for Long-Haul Comfort

Designed for breathability and precision fit, the AutoFull G7 tackles common issues like heat buildup and poor support:

  • 22 Adjustable Features for Ultimate Comfort: Includes Auto Dynamic Lumbar Support, 720° Dual-Axis Rotating Armrests, and 4D Dual-Axis Cervical Support Pillow for all-around support.
  • Cloud-Sense Shock Absorption Mesh: Durable, breathable woven mesh delivers soft, stable comfort that won’t sag—even during marathon gaming.
  • Customizable Back Armor: Personalize your gaming chair.

Shaping the Future of Esports Gear

NiKo highlights the importance of high-performance seating in competitive play. His partnership with AutoFull reflects a shared mission: to deliver next-gen gear that empowers gamers to compete at their peak—whether at home or on the world stage.

BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth

  • International recognition of quality system with GMP-compliance in the key markets of Brazil, Indonesia, Egypt, Colombia and Argentina
  • Passed its first-ever on-site PIC/S audit, reinforcing its strong commitment to stringent international regulatory standards
  • Demonstrated BioDlink’s capability to develop and deliver globally trusted biosimilars, especially antibody drugs, with proven consistency and reliability

SUZHOU, China, May 21, 2025 /PRNewswire/ — BioDlink has achieved a significant milestone in regulatory compliance after successfully passing an on-site GMP inspection conducted by Brazil’s National Health Surveillance Agency (ANVISA), a member of PIC/S (Pharmaceutical Inspection Co-operation Scheme). This is the first time BioDlink’s production site and quality systems have passed an official on-site GMP audit by a PIC/S member country which is a milestone certification for the internationalization of BioDlink’s quality system.

This inspection focused on the company’s commercial production site in Suzhou and specifically reviewed the manufacturing of its Pusintin® (bevacizumab) injection, a broad-spectrum anti-VEGF monoclonal antibody treating metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC) and metastatic colorectal cancer (mCRC). Kexing BioPharm, the global licensee for Pusintin® in emerging markets, worked closely with BioDlink to support this ANVISA inspection.

This inspection was conducted according to the rigorous guidelines of PIC/S and Brazil’s national GMP regulations, laying a strong foundation for expanding Pusintin®, an antibody developed and manufactured by BioDlink, worldwide. Over one week, ANVISA inspectors thoroughly examined the BioDlink site’s manufacturing, quality testing, storage, utility systems, and overall quality management, providing a top rating with full approval and no observations.

BioDlink’s Suzhou facility—now certified by regulatory authorities in five countries, such as Brazil, Indonesia, Egypt, Colombia and Argentina—spans 50,000 square meters and integrates perfusion fed-batch technology, streamlining antibody production and reducing costs. With four complete production lines, and an annual capacity of 300,000 liters of antibody drug substance, this site supports scalable and regulatory-compliant Pusintin® production for global markets.

As of recent estimates, the Indonesian pharmaceutical market is valued at around USD 10–12 billion, and growing at a CAGR of 10-12% 【1, making it the largest in Southeast Asia. With Indonesia already issuing a PIC/S-based GMP certification to BioDlink’s Suzhou site, the company is well-positioned to serve Southeast Asian and Indonesian pharmaceutical demand. With lung cancer 【2 being a leading cause of death in Indonesia in the past decade, further Pusintin® rollout aligns with Indonesia’s increasing investments in oncology care and biosimilar integration.

“Clearing our first on-site GMP audit by a PIC/S member signals more than compliance—it demonstrates BioDlink’s capability to develop and deliver globally trusted biosimilars, especially antibodies, with quality and consistency,” said Dr. Jun Liu, CEO and Executive Director of BioDlink. “With Pusintin® and our strong strategic alliance with Kexing Biopharm, we have initiated overseas registration for Pusintin® in over 30 countries and regions, aiming to make high-quality oncology biologics more affordable and accessible across Latin America, Southeast Asia, and the Middle East.”

” Since 2022, our partnership with BioDlink has given us the confidence that we are delivering exceptional levels of technical rigor and reliability in manufacturing—crucial for the complex CMC development and manufacturing of biosimilar drugs, which usually are much more challenging.  This GMP certification from Brazil, one of the key markets, is a powerful validation of our collaboration’s ongoing global expansion strategy,” said Dr. Kelvin Shao, Vice President of Kexing BioPharm. “We are truly proud to celebrate this achievement together with our partners, as we continue working side by side to bring global standards, and affordable oncology treatments where they’re needed most to make biosimilars more accessible worldwide.”

About PIC/S

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) was established in 1995 as an extension to the Pharmaceutical Inspection Convention (PIC) of 1970. PIC/S is an international cooperation platform that comprises 56 participating authorities coming from all over the world (Europe, Africa, America, Asia and Australasia). It leads the international development, implementation, and maintenance of harmonized GMP standards and quality systems of Inspectorates in the field of medicinal products.

Learn more:https://picscheme.org/en/about

About BioDlink Biopharm Co., Ltd.

BioDlink was established in 2010, and has a large-scale commercial GMP production base for biological drugs, a total manufacturing capacity exceeding 20,000 liters. Guided by its “Empowering Innovation with Quality to Grow Together” mission, BioDlink is dedicated to advancing global healthcare through excellence in biosimilars.

The company has built integrated platforms for biosimilars and bioconjugates, offering process development, scale-up, and quality analytics solutions. Its scalable manufacturing lines include top-tier OEB-5 facilities for high-potency ADCs, with commercial antibody production already underway.

BioDlink’s quality management system complies with regulatory requirements in China, the U.S., the EU, and Japan. In addition, the company has already passed nearly 100 GMP audits, including a zero-defect EU QP audit, with its quality systems earning worldwide recognition.

About Kexing Biopharm Co., Ltd.

Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the integration of R&D, production and sales of recombinant protein drugs and microecological preparations. It focuses on antiviral, tumor and immune, blood, digestion, degenerative diseases and other therapeutic fields, builds cutting-edge biotechnology platforms such as new protein, new antibody, nucleic acid drugs, and adheres to the platform driven development model of “innovation+internationalization”, At the same time, it explores the extensive application of biotechnology in the field of general health, actively cultivates and incubates new industries, the world’s leading industrial platforms such as animal vaccines and synthetic organisms have been distributed, and is committed to becoming a leader in high-quality biopharmaceutics and serving global patients.

Reference:

1.     NADFC (BPOM) Regulation of Pharmaceuticals in Indonesia https://www.artixio.com/post/nadfc-bpom-regulation-of-pharmaceuticals-in-indonesia

2.     Lung Cancer in Indonesia https://www.sciencedirect.com/science/article/pii/S1556086423006317

Contact information

PR name: Fiona Wu
E-mail: pr@biodlink.com

 

OKX and McLaren F1 Team Reveal Riviera Livery Honoring F1 Heritage

MONACO, May 21, 2025 /PRNewswire/ — OKX, a leading global blockchain technology company and Official Primary Partner of the McLaren Formula 1 Team, along with McLaren Racing, today revealed a striking Riviera-inspired livery that will feature on McLaren’s MCL39 race cars at the upcoming 2025 Monaco and Spanish grands prix.

Monaco Heritage Livery 2025
Monaco Heritage Livery 2025

More than a visual statement, this livery represents a shared vision of transformation. It blends the spirit of the McLaren F1 Team’s 1960’s racing triumphs with the next generation of speed, simplicity, and digital creativity, fusing old-school grit with new-school style. It is also a mark of respect for the anniversary of the tragic passing of Bruce McLaren on June 2, 1970.

Just as the M7A broke new ground in 1968, delivering McLaren its first F1 win and introducing the now-legendary papaya, this new design marks a new milestone: OKX becoming the first cryptocurrency exchange to receive a MiCA license, opening the door to a New Alternative in European finance.

Watch the video here

This campaign is the fourth custom livery born from the OKX-McLaren partnership, highlighting a shared commitment to creativity, performance, and pushing boundaries. Celebrating the legacy of old money through the lens of new money.

“Over the years, Formula 1 has seen huge amounts of change, from technological developments to the recent growth in fandom, the sport’s culture has evolved and there’s a fantastic attitude of freedom to push the boundaries of what’s possible,” said Haider Rafique, Chief Marketing Officer, OKX. “This aligns perfectly with our mission to challenge conventional ways of thinking about money and finance and Riviera livery symbolizes this transformation and the elegance and innovation both OKX and McLaren are known for.”

Fans can look forward to seeing the Riviera-inspired livery on both McLaren MCL39s, driven by Lando Norris and Oscar Piastri, who will also wear exclusive OKX-branded A New Alternative race suits during the Monaco Grand Prix weekend.

From the sun-drenched streets of Monaco to the global stage of financial innovation, the Riviera livery connects McLaren’s legacy with OKX’s vision: a world where tradition meets transformation, old money gives way to new freedom, and boldness knows no boundaries.

About OKX

Trusted by more than 60 million customers around the globe, OKX is a technology company building a decentralized future that makes the world more tradable, transparent and connected. We’re known for being one of the fastest and most reliable crypto apps in the world, and have processed trillions of dollars in transactions.

We have key regional offices, including headquarters in San José, California, for the Americas and in Dubai for the Middle East. We also have offices in New York, Hong Kong, Singapore, the Republic of Türkiye, Australia and Europe.

Over the past several years, we’ve built one of the world’s most comprehensive regulatory compliant, licensed crypto companies. We hold licenses in the United States, the UAE, EEA, Singapore and Australia, as well as in other markets.

We’re steadfastly committed to transparency and security and publish Proof of Reserves reports on a monthly basis. To learn more about OKX, download our app or visit: okx.com.

Disclaimer

About McLaren Racing

McLaren Racing was founded by racing driver Bruce McLaren in 1963. The team entered its first Formula 1 race in 1966. McLaren has since won 21 Formula 1 world championships, 193 Formula 1 Grands Prix, the Indianapolis 500 three times, and the Le Mans 24 Hours at its first attempt. 

McLaren Racing competes across five racing series. The team competes in the FIA Formula 1 World Championship with McLaren F1 drivers Lando Norris and Oscar Piastri, the NTT INDYCAR SERIES with Arrow McLaren drivers Pato O’Ward, Nolan Siegel and Christian Lundgaard, the ABB FIA Formula E World Championship as the NEOM McLaren Formula E Team with drivers Sam Bird and Taylor Barnard, and F1 Academy with Driver Development programme member Ella Lloyd. The team also competes in the F1 Sim Racing Championship as McLaren Shadow with Lucas Blakeley, Wilson Hughes and Alfie Butcher.

McLaren is a champion for sustainability in the sport and a signatory to the UN Sports for Climate Action Commitment. It is committed to achieving net zero by 2040 and fostering a diverse and inclusive culture in the motorsport industry.

McLaren Racing – Official Website

Google Announces Partnership with Gentle Monster as a First Partner for AI Smart Eyewear with Android XR

SINGAPORE, May 21, 2025 /PRNewswire/ — Google announced at I/O 2025 its partnership with Gentle Monster as a first partner for an AI smart eyewear collaboration with Android XR.

Google partnership with GENTLE MONSTER
Google partnership with GENTLE MONSTER

Gentle Monster is a global eyewear brand from South Korea, leading the trends in global eyewear through its innovative brand narrative with experimental yet sophisticated aesthetics.

Shahram Izadi, General Manager and Vice President, Google XR, emphasized that creativity and sophistication are essential design features for technology to integrate into everyday life. Gentle Monster as a first partner in the development of AI smart eyewear with Android XR was also highlighted as a pivotal step in the evolution of AI smart eyewear into essential, lifestyle fashion items.

Envisioning easy-to-wear products with both comfort and aesthetics as top priorities, the new partnership with Gentle Monster is set to seamlessly integrate extended reality into everyday life.

The announcement at Google I/O 2025 has sparked considerable anticipation for the eyewear that will showcase cutting-edge smart technology alongside the refined aesthetics of Gentle Monster.

Fibocom Releases 5G AI Mobile Hotspot Solution, Unlocking Intelligent Future for Mobile Broadband Devices

TAIPEI , May 21, 2025 /PRNewswire/ — As 5G and AI technologies continue to converge, demand is growing for stable, high-speed, and intelligent mobile networks across various scenarios—from business travel and outdoor operations to global connectivity. Fibocom’s latest 5G AI Mobile Hotspot solution redefines the mobile broadband experience with cutting-edge technology and forward-thinking design.

Powered by Qualcomm’s advanced 4nm QCM4490 platform, the solution combines smartphone-grade ultra-low power consumption with precision circuit design. This results in a powerful yet energy-efficient platform that balances high performance with cost optimization.

In terms of connectivity, the solution supports 3GPP Release 16 and NR 2CC 120MHz. It delivers a downlink speed of up to 2.3 Gbps in SA mode and 2.5 Gbps in NSA mode. Customers can flexibly configure the solution with either AX3600-based Wi-Fi 6E or BE5800-based Wi-Fi 7 options. It supports dual-band simultaneous (DBS) modes of 2.4GHz+5GHz or 2.4GHz+6GHz, as well as high-band simultaneous (HBS) mode of 5GHz+6GHz.

Tailored for Mobile Hotspot applications, the solution runs an optimized Android 13 OS, significantly boosting system performance while reducing power consumption. With USB 3.1 support and a theoretical data transfer rate of up to 5 Gbps, it’s well-suited not only for 5G Mobile Hotspot devices but also for other mobile broadband terminals such as USB dongles.

Crucially, the solution leverages the QCM4490’s heterogeneous computing architecture, featuring a robust 8-core CPU (2x Cortex-A78 @ 2.4GHz + 6x Cortex-A55 @ 2.0GHz) and integrated Adreno 613 GPU (@ 1010MHz). Compared to GPU-less solutions, this powerful combination enables efficient on-device AI processing, expanding the possibilities for more edge intelligence applications. Internal tests have demonstrated the successful deployment of large-scale open-source AI models such as Qwen-1.8 B-Chat.

From business office to global travel these mobile broadband applied scenarios, Fibocom’s cost-effective 5G AI Mobile Hotspot solution—with optional Wi-Fi 7 support—paves the way for a new era of AI-enhanced mobile broadband. Welcome to visit Fibocom’s booth #K0727a at COMPUTEX 2025 to explore firsthand how its AI-powered connectivity solutions are unlocking the intelligent future of diversified industries.

China’s Aphranel MagiCCrystal CaHA Filler Debuts Globally, Ushering in a New Era of Regenerative Aesthetic Medicine

SHANGHAI, May 21, 2025 /PRNewswire/ — On May 8, 2025, Shanghai Moyom Biotechnology Co., Ltd. unveiled its breakthrough regenerative aesthetic innovation, Aphranel MagiCCrystal CaHA Filler, during an international product debut at The Grand Halls in Shanghai, a historic building on the Bund. 

 

Presented under the theme “APHRANEL: Code Breaker, World Maker, the event welcomed senior policy makers, including Wu Changfei and Li Wei, as well as Ren Dawei, Deputy Director of the Shanghai Center for Biomedicine Development, who delivered the opening remarks. The scientific program featured keynote lectures from internationally recognized experts in plastic and aesthetic surgery—Prof. Qi Zuoliang, Prof. Cui Haiyan, Prof. Luo Shengkang, Prof. Chen Guangyu, Prof. Li Ya, and Dr. Stefan Lipp from Germany. The launch drew participation from physicians, key opinion leaders, and medical aesthetics associations, underscoring China’s growing role in the development of next-generation regenerative materials for aesthetic applications. 

China’s First Class III CaHA Filler Gains Global Regulatory Clearance

Aphranel MagiCCrystal CaHA Filler is the first injectable calcium hydroxylapatite (CaHA) microsphere-based dermal filler developed in China to receive NMPA Class III medical device certification. The formulation is engineered using proprietary manufacturing processes that allow precise modulation of particle size, porosity, and degradation rates. The filler’s ACD-MT™ “raspberry-like” through-hole microsphere morphology and PCD-ETT™ physically crosslinked gel matrix contribute to its favorable safety profile, structural integrity, and tissue integration—features that align with global standards in regenerative injectables.

The product has obtained EU Medical Device certification, MDSAP compliance, and regulatory clearance from Mexico’s COFEPRIS, enabling simultaneous market access across Asia, Europe, and Latin America. These designations mark a significant regulatory and scientific milestone for China-origin biomaterials in the global aesthetic sector.

World’s Top Plastic Surgeons Endorse Groundbreaking Chinese Formula

Lin Guangming, Chairman of Moyom Biotechnology, highlighted the company’s decade-long R&D journey during the product launch, emphasizing its commitment to “restoring the medical essence of aesthetic treatments”. This scientific rigor has enabled China’s transition from industry follower to global innovator, with Aphranel now delivering a precision-engineered “Chinese Solution” for controlled degradation and targeted anti-aging. 

The ceremonial highlight featured a butterfly release ceremony symbolizing the product’s transformation-driven therapeutic value. Moyom also announced 68 newly established clinical collaborations with global medical aesthetics centers, forming the basis for long-term multicenter studies and physician education initiatives. 

A clinical and scientific roundtable moderated by Moly.Nice founder Xiaodong brought together leading researchers and practicing clinicians to assess Aphranel’s bioengineering underpinnings. The expert panel validated the product’s therapeutic concept and endorsed its potential as a future standard in precision-based aesthetic medicine. Emphasis was placed on the brand’s “butterfly transformation” approach, with discussion centered on its relevance to longevity, safety, and patient-specific treatment outcomes. 

The launch concluded with a gala dinner co-presented by Shanghai Theatre Academy, featuring a groundbreaking fusion of jazz, classical, ballet and opera. The performance was designed to echo the product’s brand narrative of renewal and aesthetic harmony, presenting an East-West artistic dialogue that resonated with the event’s global audience.

https://youtu.be/OeW6k6jSrV4

China Sets New Global Benchmark in Anti-Aging Treatments
“Aphranel demonstrates how ‘Created in China‘ can achieve global excellence through medical innovation,” said Chairman Lin. “The innovation establishes new benchmarks for aesthetic safety and natural results worldwide.”

About Shanghai Moyom Biotechnology
Shanghai Moyom Biotechnology is a national high-tech enterprise and leading developer of premium medical aesthetic solutions. Specializing in nano-medical biomaterials and Class III absorbable implants, the company drives innovation across R&D, manufacturing, and clinical applications.